_edited.png)
NY Approves First U.S. THC Oral Solution Trial for Sciatica Pain
Fast Facts
Who / Where: New York Cannabis Control Board, Office of Cannabis Management, Vertanical GmbH, Upstate Clinical Research Associates
What changed: New York approved a clinical trial for the THC oral solution VER-01 to treat chronic sciatica pain
Effective / Key date: 2026-10-08
Status: Approved, study recruitment and research beginning
DMV impact: No immediate access changes; illustrates the pace and rigor of research shaping future DMV policy
The bottom line: On October 8, 2026, New York regulators approved the first U.S. clinical trial to assess the safety and effectiveness of VER-01, a THC-based oral solution developed by Vertanical GmbH, for patients with chronic sciatica pain whose symptoms are not managed by non-opioid medications.
Medical cannabis research in the U.S. just cleared an important milestone. The New York Cannabis Control Board (CCB) has authorized a rigorous clinical trial to evaluate a THC-rich oral cannabis extract, VER-01, as a potential therapy for chronic pain caused by sciatica—also known as lumbosacral radiculopathy. If successful, this program could shift how chronic pain patients nationwide access and use medical marijuana, while also accelerating evidence-based cannabis policy discussions in the District of Columbia, Maryland, and Virginia.
What Is the New York Medical Cannabis Trial for VER-01?
The New York Cannabis Control Board and Office of Cannabis Management approved a unique clinical study assessing whether the oral THC solution VER-01 is more effective than placebo for relieving pain in patients with chronic lumbosacral radiculopathy (sciatica). This is one of the first U.S. clinical trials to test a cannabis-derived medicine for chronic pain using gold-standard research protocols.
The study is being led by Upstate Clinical Research Associates. Research sites are opening in New York and other U.S. states, with patient recruitment already underway, according to Ganjapreneur and Pain News Network. The trial only enrolls adults whose sciatica pain persists despite using non-opioid analgesics. Participants will receive either VER-01 or placebo, allowing investigators to assess both efficacy and safety, including possible side effects over time.
How Does the New York Trial Work?
The study will use VER-01, an oral full-spectrum cannabis extract developed by the German pharmaceutical company Vertanical GmbH and known as Exilby in Europe. This extract contains THC, CBD, and natural cannabis terpenes, formulated specifically for chronic pain rather than seizure disorders or appetite issues.
Researchers, including lead investigator Dr. James E. Wild, will carefully monitor participants for both pain relief and any adverse outcomes, maintaining strict patient safety and scientific integrity protocols. The initiative is part of a broad push to advance cannabis medicines through rigorous, FDA-style clinical research, in line with other approved drugs (such as Epidiolex or Marinol) but targeting a new set of symptoms and conditions.
When Will the New York Medical Cannabis Study Launch?
The New York trial of VER-01 received official regulatory authorization on October 8, 2026, but participant recruitment and data collection are ongoing. Enrollment of over 800 adults is taking place at more than twenty U.S. study sites, including in Texas, as reported by Pain News Network. Preliminary data and regulatory review will take years; a formal FDA application for VER-01 is not expected before 2028.
Scientific Evidence and Research Findings
VER-01 has already been evaluated in European studies, where it demonstrated superior pain relief over low-dose opioids in patients with chronic low back pain. However, this is the first time a full-spectrum THC/CBD oral solution designed for pain—not for epilepsy—is being systematically studied in an FDA-like clinical trial setting in the U.S.
According to Ganjapreneur and Pain News Network, the evidence so far suggests that THC, when combined with other cannabis compounds and delivered orally in a measured solution, may offer sustained pain control for some patients who have failed conventional non-opioid treatments. Previous U.S. drug approvals for cannabis-based medicines (Marinol, Epidiolex) have focused on nausea and seizures; no such product is FDA-approved for chronic musculoskeletal pain.
Provision | Previous Rule | New Rule | Effective Date |
|---|---|---|---|
Legal research access to cannabis for pain trials | Highly restricted, few trials for pain using whole-plant cannabis | VER-01 clinical trial authorized for sciatica pain | 2026-10-08 |
FDA-approved cannabis products for pain | None | Expedited trial process for VER-01 | 2026-10-08 (Breakthrough Therapy designation in March 2026) |
Availability of full-spectrum oral THC extracts | Not available in U.S. for pain | Clinical trial allows patient use under supervision | 2026-10-08 |
European market status | Exilby approved in Germany, Austria | Pending UK approval, broader research ongoing | September 2026 (EU); U.K. pending |
Medical Applications and Patient Benefits
The current trial is limited to patients with chronic sciatica (lumbosacral radiculopathy) whose symptoms have not responded to non-opioid pain medication, a group that often faces complex treatment decisions and risks associated with long-term opioid use. For eligible individuals, especially those who have not benefited from NSAIDs or acetaminophen, or have experienced side effects from these drugs, the VER-01 oral solution could potentially provide an alternative with a different risk profile.
Unlike inhaled cannabis or edible gummies, VER-01 is delivered as a standardized oral solution—making dose titration, absorption, and safety monitoring more precise. This aligns with clinical best practices and may help pave the way for more consistent patient experiences, which remain a challenge with other medical marijuana delivery methods.
Safety Considerations and Side Effects
All cannabis-derived medicines can present side effects, and the clinical trial is designed to identify both short-term and long-term safety signals in a controlled setting. The FDA "Breakthrough Therapy" designation for VER-01, granted in March 2026, expedites research on its safety and efficacy.
Potential side effects of THC-based oral solutions can include dizziness, cognitive effects, fatigue, gastrointestinal upset, mood changes, and risk of dependency with long-term use. The trial will measure these closely, as well as any adverse events related to drug-drug interactions (especially for patients using other pain medications). Regulatory oversight aims to ensure that benefits outweigh the risks, which is why data maturation and multi-year follow-up are critical before considering widespread patient access outside the clinical setting.
What Does This Mean for DC, Maryland and Virginia?
For residents of Washington DC, Maryland, and Virginia, the New York VER-01 trial underscores the slow but steady movement toward true science-backed cannabis medicines. As of June 2024, DC allows adult use and gifting under Initiative 71, but legal home delivery and sales remain in legal gray areas, while Virginia has decriminalized possession and continues to debate how medical and adult-use markets will be structured. Maryland's medical cannabis program is robust, yet products for chronic pain still vary greatly in quality and formulation.
What happens in New York will likely shape standards for what "medical marijuana" really means in the DMV. If VER-01 or similar products ultimately gain FDA approval after U.S. trials are done, prescribers and patients could see a shift from mostly self-directed cannabis use (flower, edibles, concentrates) toward true, regulated cannabis pharmaceuticals—potentially expanding future options for everything from delivery services to patient dosing guidance. Until then, DC and Maryland patients should talk to their certifying providers about available product types, responsible delivery options, and relevant patient protections under their state laws.
How Does VER-01 Differ from Other Medical Cannabis Options?
VER-01 is formulated as a full-spectrum, pharmaceutical-grade oral solution containing a specific ratio of THC, CBD, and terpenes. Unlike unregulated cannabis flower or generic edibles available from DC dispensaries or through Maryland and Virginia programs, VER-01's composition, dosage, and administration are standardized—a requirement for FDA consideration. Most current U.S. cannabis-based medicines are either single-molecule THC (Marinol) or CBD (Epidiolex); neither is approved for general pain management.
For DMV patients exploring dosing and delivery, understanding the difference between regulated oral solutions and standard edibles or vapes can help inform safe choices. Oral cannabis extracts have more predictable absorption versus edibles, but may have a slower onset than inhaled products.
BUD LORDS TAKE: What Comes Next for Medical Cannabis Research?
Our read: The New York VER-01 trial marks a turning point for medical marijuana science. For years, U.S. researchers were blocked from even studying cannabis as a pain therapy. Now, as trial-grade products and standardized delivery methods like oral solutions enter the pipeline, the evidence base will catch up to public demand. But this process will take time: clinical research is cautious by design. In the DMV, expect no rapid home delivery of new oral THC medicines until the FDA and local regulators have their say. However, these studies will likely form the backbone for future policy, safer patient guidance, and perhaps insurance coverage down the road.
What is lumbosacral radiculopathy (sciatica)?
Lumbosacral radiculopathy, commonly called sciatica, is chronic nerve pain originating from the lower back and radiating down the leg, often due to compression or irritation of spinal nerves.
Who can participate in the VER-01 trial?
Adults with medically documented chronic sciatica who have not achieved adequate pain relief from non-opioid painkillers can apply. Eligibility requirements are strict and include evaluation at approved research sites.
Is VER-01 available for general prescription?
No. VER-01 is not available outside controlled study sites in the U.S. It is prescribed in select European markets (as Exilby), but U.S. approval will not be considered until after these clinical trials conclude.
How does oral THC delivery benefit patients?
Oral THC solutions may offer steady dosing, easier titration, and less variability than inhaled or edible cannabis, potentially improving safety and efficacy for select chronic pain patients.
Are there risks to THC-based pain treatments?
All cannabis medicines carry risks, including side effects, drug interactions, and possible dependence. Medical supervision is critical for safe use.
Further Resources and Medical Consultation
Read more about the New York trial on Ganjapreneur
Explore clinical trial locations and eligibility at national registries
For DC, Maryland, and Virginia residents: consult state-licensed cannabis doctors or pharmacists for individual patient guidance
Learn about safe edible dosing, delivery options, and local regulations on the Bud Lords blog
Have a cannabis story, local update, or strain you want our newsroom to cover? Request a story →
Written by California Cannabis AI
Bud Lords AI Cannabis News Writer
West Coast cannabis industry expert specializing in California's massive market, innovative businesses, tech integration, and progressive policies. Covers Silicon Valley cannabis tech, LA dispensary culture, and Sacramento policy.
Expertise: california · west-coast · tech · innovation · silicon-valley · los-angeles
This AI-assisted article was created using the named Bud Lords newsroom personality and reviewed under Bud Lords editorial standards.
Comments